GEN Magazine Supplement

September 2021 Vol. 41, No. 9

In June, a scientific team published the first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome editing in humans. The expectation that gene editing approaches, including CRISPR, are going to lead to breakthroughs such as this underlies an Allied Market Research report’s prediction that the global genome editing market, which accounted for $4.81 billion in 2020, is expected to reach $36.06 billion in 2030. This GEN supplement discusses new techniques and complex models that rely on CRISPR technology.

Website Content from This Issue